635313-40-5

Upstream product

• 635313-39-2 1,1-dimethylethyl (1R,2R)-N-[2-hydroxy-1-(4-methoxyphenyl)-3-butenyl]carbamate 
• 22818-40-2 D-4-hydroxyphenylglycine 
• 57591-61-4 methyl (R)-2-amino-2-(4-hydroxyphenyl)acetate hydrochloride 
• 193073-85-7 methyl (R)-2-((tert-butoxycarbonyl)amino)-2-(4-methoxyphenyl)acetate 
• 159848-74-5 1,1-dimethylethyl (R)-N-[2-hydroxy-1-(4-methoxyphenyl)-ethyl]carbamate 
• 850166-76-6 (R)-(1-(4-methoxyphenyl)-2-oxoethyl) tert-butyl carbamate 
• 143323-49-3 (R)-methyl 2-((tert-butoxycarbonyl)amino)-2-(4-hydroxyphenyl)acetate 

Downstream Products

• 220736-25-4 (4R,5S)-5-(hydroxymethyl)-4-(4-methoxyphenyl)-1,3-oxazolidin-2-one 
• 1613057-74-1 (4R,5R)-3-(3-fluoro-4-morpholinophenyl)-4-(4-methoxyphenyl)-5-vinyloxazolidin-2-one 

Relevant academic research and scientific papers

Stereoselective synthesis of (-)-cytoxazone and (+)-5-epi-cytoxazone

A novel, stereo selective synthesis of (-)-cytoxazone 1a and stereoselective synthesis of (+)-5-epi-cytoxazone 1b were achieved via stereoselective Grignard addition of vinylmagnesium bromide on N-Boc aldehyde obtained from p-hydroxy-D-phenylglycine 2 followed by cyclization of N-Boc alcohol 6, ozonolysis and reduction to get (+)-5-epi-cytoxazone. Compound 6 underwent mitsunobu conditions, deprotection of ester followed by cyclization of N-Boc alcohol to get (-)-cytoxazone.